- Home
- VSTD vs HOTH Comparison
VSTD vs HOTH Comparison
Compare VSTD & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | HOTH |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 18.0M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VSTD | HOTH |
|---|---|---|
| Price | $0.47 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 422.8K | 242.7K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,902,861.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.39 | N/A |
| 52 Week Low | $0.40 | $0.66 |
| 52 Week High | $5.63 | $3.80 |
Technical Indicators
Market Signals| Indicator | VSTD | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.43 |
| Support Level | N/A | $1.13 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 73.08 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).